Innate Pharma S.A. Share Price & Technical Analysis
IPHA · $1.83 (-7.11%)
Healthcare / Biotechnology
$1.83
-7.11%
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to…
Price chart
Seasonality
May has 2 positive and 1 negative years (last 5 years shown)
20% return in May, 3% avg return in past 3 year May month.
-2% return in 2026, -25% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -11% | -19% | 8% | 20% | – | – | – | – | – | – | – | -2% |
| 25 | -5% | 11% | -18% | 16% | 0% | -14% | 17% | 0% | -10% | 0% | 0% | -5% | -10% |
| 24 | -4% | 0% | 12% | -18% | 8% | -30% | 0% | 5% | 5% | -14% | -17% | 13% | -40% |
| 23 | 0% | -14% | -7% | -9% | 0% | 11% | -3% | -3% | -17% | -4% | 9% | 12% | -25% |
| 22 | -21% | -11% | -3% | -17% | -7% | -13% | 14% | -4% | -26% | 16% | 0% | 68% | -2% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Uptrend
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$131.36M
P/E ratio
—
52W high
$2.63
52W low
$1.17
Volume
14,901
Beta
0.81
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Innate Pharma S.A. share price today?
- Innate Pharma S.A. (IPHA) last traded around $1.83 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IPHA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IPHA. Download the app for real-time alerts.
- How can I analyze Innate Pharma S.A. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.